Teriflunomide
Back to Test Catalogue
Leflunomide Metabolite (Teriflunomide) LC-MS/MS, Serum
Test ID: LEFLUN
Test
Method
LC-MS/MS
Report Includes
Specimens
Avoid gel separator tubes; Serum; Plasma (Na Heparin); Plasma (Li Heparin)
Clinical Utility
Leflunomide is rapidly and extensively metabolized to teriflunomide,which is the active form of the medication. Therapeutic monitoring of teriflunomide is important to ensure adequate dosage. It is recommended that women of childbearing potential who discontinue leflunomide therapy undergo the cholestyramine drug elimination procedure.This procedure includes verification that plasma levels of teriflunomide are less than 20 ng/mL by two separate tests at least 14 days apart.
Test Location
Quest Diagnostics, California USA
Test Version
26-May-2023
Specimen
Specimens
Avoid gel separator tubes; Serum; Plasma (Na Heparin); Plasma (Li Heparin)
Sample Volume
1.0 mL
Minimum Volume
0.5 mL
Specimen Comment
Avoid gel separator tubes.
Collection & Handling
Handling Information
Store and send cold or frozen.
Stability
| Ambient | 5 days |
|---|---|
| Refrigerated | 14 days |
| Frozen | 30 days |
Rejection Criteria
| Specimen | Gel-separator tubes |
|---|
Test Version
26-May-2023
Performance / Interpretation
Method
LC-MS/MS
Turnaround Time
10 days
Results
| Name | Units | Reference Range | Conversion Factor | |
|---|---|---|---|---|
| Leflunomide Metabolite | ng/mL |
|
||
|
Mean steady state plasma concentrations of teriflunomide from patients on daily dosages of 5, 10, or 25 mg of leflunomide were 8,800, 18,000 and 63,000 ng/mL, respectively.
|
||||
Test Location
Quest Diagnostics, California USA
Test Version
26-May-2023
Interface / Setup
HL7 Interface Codes
| Order Code | Result Codes | Units |
|---|---|---|
| LEFLUN | 38058TERIFLUNOMIDE | ng/mL |
Test Version
26-May-2023